Amantadine Therapy for Fatigue in Multiple Sclerosis

Open Access
Publisher Website
Google Scholar
Abstract
A double blind control study of fatigue was carried out in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo. On amantadine 31% had marked improvement; 15.6% moderate improvement; 15.6% mild improvement and 36.5% unchanged. On placebo, none noted marked improvement; 1 claimed moderate improvement on either amantadine or placebo; and 18.7% reported mild improvement of placebo. Most of them had a similar or more than similar response to amantadine. No patient selected placebo over amantadine at the end of the trial. Overall improvement was seen in 62.5% of patients on amantadine and 21.8% on placebo. Additional experience up to 2 yr suggests continued benefit, but common and important side-effects.

This publication has 8 references indexed in Scilit: